Maywufa Company Ltd. (1731.TW)
TWD 22.75
(-0.66%)
TWD 22.75
(-0.66%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 442.66 Million TWD | 95.01% |
| 2022 | 227 Million TWD | -28.43% |
| 2021 | 317.15 Million TWD | 4.05% |
| 2020 | 304.81 Million TWD | -4.74% |
| 2019 | 319.98 Million TWD | 5.97% |
| 2018 | 301.95 Million TWD | 49.19% |
| 2017 | 202.39 Million TWD | -0.04% |
| 2016 | 202.46 Million TWD | -0.35% |
| 2015 | 203.18 Million TWD | 0.23% |
| 2014 | 202.72 Million TWD | -33.1% |
| 2013 | 303.01 Million TWD | -0.5% |
| 2012 | 304.54 Million TWD | 0.59% |
| 2011 | 302.76 Million TWD | -37.47% |
| 2010 | 484.19 Million TWD | 6.15% |
| 2009 | 456.13 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 577.28 Million TWD | 10.22% |
| 2024 Q1 | 523.76 Million TWD | 18.32% |
| 2023 FY | 442.66 Million TWD | 95.01% |
| 2023 Q1 | 258.28 Million TWD | 13.78% |
| 2023 Q2 | 289.81 Million TWD | 12.21% |
| 2023 Q4 | 442.66 Million TWD | 8.1% |
| 2023 Q3 | 409.5 Million TWD | 41.3% |
| 2022 Q3 | 142.85 Million TWD | 1028.7% |
| 2022 Q2 | 12.65 Million TWD | -95.98% |
| 2022 FY | 227 Million TWD | -28.43% |
| 2022 Q4 | 227 Million TWD | 58.9% |
| 2022 Q1 | 314.91 Million TWD | -0.71% |
| 2021 Q1 | 303.03 Million TWD | -0.58% |
| 2021 FY | 317.15 Million TWD | 4.05% |
| 2021 Q2 | 305.75 Million TWD | 0.9% |
| 2021 Q4 | 317.15 Million TWD | -0.63% |
| 2021 Q3 | 319.18 Million TWD | 4.39% |
| 2020 FY | 304.81 Million TWD | -4.74% |
| 2020 Q1 | 316.4 Million TWD | -1.12% |
| 2020 Q2 | 313.6 Million TWD | -0.88% |
| 2020 Q3 | 311 Million TWD | -0.83% |
| 2020 Q4 | 304.81 Million TWD | -1.99% |
| 2019 Q1 | 329 Million TWD | 8.96% |
| 2019 FY | 319.98 Million TWD | 5.97% |
| 2019 Q2 | 325.63 Million TWD | -1.02% |
| 2019 Q4 | 319.98 Million TWD | -1.37% |
| 2019 Q3 | 324.41 Million TWD | -0.37% |
| 2018 Q4 | 301.95 Million TWD | -0.19% |
| 2018 Q1 | 302.39 Million TWD | 49.41% |
| 2018 Q2 | 302.66 Million TWD | 0.09% |
| 2018 Q3 | 302.53 Million TWD | -0.04% |
| 2018 FY | 301.95 Million TWD | 49.19% |
| 2017 Q1 | 202.21 Million TWD | -0.12% |
| 2017 FY | 202.39 Million TWD | -0.04% |
| 2017 Q4 | 202.39 Million TWD | -0.02% |
| 2017 Q3 | 202.43 Million TWD | 0.43% |
| 2017 Q2 | 201.56 Million TWD | -0.32% |
| 2016 Q2 | 201.34 Million TWD | -1.02% |
| 2016 Q1 | 203.41 Million TWD | 0.12% |
| 2016 FY | 202.46 Million TWD | -0.35% |
| 2016 Q4 | 202.46 Million TWD | -0.48% |
| 2016 Q3 | 203.44 Million TWD | 1.04% |
| 2015 Q4 | 203.18 Million TWD | -0.17% |
| 2015 FY | 203.18 Million TWD | 0.23% |
| 2015 Q2 | 203.07 Million TWD | -0.25% |
| 2015 Q3 | 203.51 Million TWD | 0.22% |
| 2015 Q1 | 203.59 Million TWD | 0.43% |
| 2014 Q3 | 203.89 Million TWD | -32.7% |
| 2014 Q2 | 302.96 Million TWD | -0.18% |
| 2014 FY | 202.72 Million TWD | -33.1% |
| 2014 Q1 | 303.5 Million TWD | 0.16% |
| 2014 Q4 | 202.72 Million TWD | -0.58% |
| 2013 Q3 | 303.28 Million TWD | -0.53% |
| 2013 Q4 | 303.01 Million TWD | -0.09% |
| 2013 FY | 303.01 Million TWD | -0.5% |
| 2013 Q1 | 304.97 Million TWD | 0.14% |
| 2013 Q2 | 304.89 Million TWD | -0.03% |
| 2012 Q1 | 303.2 Million TWD | 0.14% |
| 2012 Q3 | 302.68 Million TWD | -0.36% |
| 2012 Q4 | 304.54 Million TWD | 0.62% |
| 2012 FY | 304.54 Million TWD | 0.59% |
| 2012 Q2 | 303.76 Million TWD | 0.19% |
| 2011 Q4 | 302.76 Million TWD | 0.08% |
| 2011 FY | 302.76 Million TWD | -37.47% |
| 2011 Q1 | 309.51 Million TWD | -36.08% |
| 2011 Q3 | 302.52 Million TWD | 0.3% |
| 2011 Q2 | 301.6 Million TWD | -2.56% |
| 2010 Q4 | 484.19 Million TWD | 0.0% |
| 2010 FY | 484.19 Million TWD | 6.15% |
| 2009 FY | 456.13 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -129.456% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | 59.088% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | 28.729% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 96.179% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -16693.096% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 64.285% |
| PhytoHealth Corporation | 28.11 Million TWD | -1474.483% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | 57.537% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 89.109% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 63.118% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 91.164% |